10 results
10-K
2021 FY
GLUE
Monte Rosa Therapeutics Inc
29 Mar 22
Annual report
4:15pm
with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
Risks related to our dependence on third
10-Q
2021 Q2
GLUE
Monte Rosa Therapeutics Inc
12 Aug 21
Quarterly report
4:22pm
result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
Risks related to our dependence on third parties
We
424B4
GLUE
Monte Rosa Therapeutics Inc
25 Jun 21
Prospectus supplement with pricing info
6:08am
. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
Risks
S-1/A
f1gw djbrtecsa5f
9 Jun 21
IPO registration (amended)
4:51pm
S-1
7rtjza5sybwmhavgz9
4 Jun 21
IPO registration
9:07am
DRS/A
wfm1f wo1
21 May 21
Draft registration statement (amended)
12:00am
DRS
q9qnpi39
19 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next